IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
Portfolio Pulse from
IN8bio, Inc. (Nasdaq: INAB) reported positive results from its Phase 1 trial of INB-100 in acute myeloid leukemia (AML) patients, with all patients remaining in complete remission and showing improved survival rates compared to control groups.
February 11, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's Phase 1 trial of INB-100 shows 100% remission in AML patients, with improved survival rates. This positive data could boost investor confidence and impact stock prices favorably.
The announcement of 100% remission in AML patients and improved survival rates from the Phase 1 trial of INB-100 is a significant milestone for IN8bio. This positive clinical data is likely to increase investor confidence in the company's innovative therapies, potentially leading to a rise in stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100